1 / 13

Small Bowel Toxicity of Nonselective NSAIDs Revealed by Capsule Endoscopy: Results From a Pivotal Clinical Trial

Small Bowel Toxicity of Nonselective NSAIDs Revealed by Capsule Endoscopy: Results From a Pivotal Clinical Trial. Glenn M. Eisen, M.D., M.P.H. Associate Professor of Medicine Oregon Health and Science University, Portland, Oregon. NSAIDs and Small Intestinal Damage. 10. * 8.4%. 8.

weldon
Télécharger la présentation

Small Bowel Toxicity of Nonselective NSAIDs Revealed by Capsule Endoscopy: Results From a Pivotal Clinical Trial

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Small Bowel Toxicity of Nonselective NSAIDs Revealed by Capsule Endoscopy: Results From a Pivotal Clinical Trial Glenn M. Eisen, M.D., M.P.H. Associate Professor of Medicine Oregon Health and Science University, Portland, Oregon

  2. NSAIDs and Small Intestinal Damage 10 * 8.4% 8 NSAID group (n = 249) Control group (n = 464) 6 % of Subjects With Small Intestinal Ulcers 4 2 0.6% 0 Nonspecific ulcers *P < 0.001 Allison, et al. N Engl J Med. 1992;327:749–754.

  3. Patients NSAID Use P Value OR AOR Controls 34% – – – UGIB 60% < 0.001 3.0* 3.2 LGIB 60% < 0.001 3.0* 2.6* NSAID Use Is Associated With Both Upper and Lower GI Bleeding • Case-controlled study of upper GI bleeding (UGIB) and lower GI bleeding (LGIB) • Use of NSAIDs within 1 week of admission was documented * P < 0.05 OR = odds ratio; AOR = OR adjusted for age, race, and gender. Wilcox CM, et al. Dig Dis Sci. 1997;42:990–997.

  4. Rates of Serious Lower GI Events per 100 Patients-Years in Patients Receiving Rofecoxib vs Naproxen Relative Risk (95% CI) 0.46(0.22-0.93) P = 0.03 1.0 0.89 0.8 Rofecoxib 0.6 % of Patients with Serious Lower GI Events per 100 Patient-Years (n = 4,047) 0.41 Naproxen 0.4 (n = 4,029) 0.2 0 Laine, et al. Gastroenterology. 2003;124:288-292.

  5. CLASS: Decreases in Hct ≥ 10% and/or Hgb > 2 g/dL 10 Celecoxib Diclofenac Ibuprofen 8 * 5.7 * 4.5 6 * 3.7 * 4.4 % of Patients 4 2.4 2.0 2 0 All Patients Patients Without Complications *P < 0.05 vs celecoxib FDA Arthritis Advisory Committee Meeting. February 7, 2001. Gaithersburg, Maryland, USA.

  6. Hypothesis The combination of a non-specific NSAID + PPI will be associated with a rate of small bowel mucosal breaks that is significantly higher than the rate for placebo or for a COX-2 specific inhibitor

  7. Inside the M2A Capsule

  8. NSAID-Induced Lesions

  9. Study Design Start study drug Naproxen 500 mg BID plus omeprazole 20 mg QD 2-week run-in period Healthy Subjects Celecoxib 200 mg BID Placebo 2-week Tx period Screening Randomization Final M2A video capsule (final) M2A video capsule (baseline)

  10. Primary End Point (mITT) Mean Number of Small-Bowel Mucosal Breaks (Grades 2, 3, 6, and 7) P < 0.001 P < 0.001 3 2.99 2 Mean # of SB Mucosal Breaks (Grades 2, 3, 6, and 7) 1 0.32 0.11 0 Celecoxib (n = 115) Naproxen + PPI (n = 111) Placebo (n = 113) P = 0.042 Goldstein J, Eisen G, Gralnek I, Clin Gastroenterol and Hepatol Feb 2005

  11. Capsule Endoscopy StudySecondary End Point (mITT) Incidence of Small Bowel Mucosal Breaks *Across three treatments corresponding to general association of the Cochran-Mantel-Haenszel test having stratified by site

  12. Conclusions • As in the upper GI tract, inhibition of COX-1 by naproxen and not celecoxib translates into significantly different rates of mucosal injury in the small bowel • These findings extend the original COX-1 sparing hypothesis beyond the upper GI tract and into the small bowel

  13. Conclusions (2) • Use of NS-NSAIDs can potentially lead to mucosal lesions, gastrointestinal bleeding beyond the ligament of Treitz • PPI use does not protect against NSAID induced damage to the small/large intestine • Capsule endoscopy provides a noninvasive assessment of the small bowel, which may be clinically useful in patients at risk for small bowel injury

More Related